PEAK6 Investments’s Myriad Genetics MYGN Stock Holding History

PEAK6 Investments’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-38,300	Closed	-$731K	–	4940
2022 Q3	$731K	Hold	38,300	–	–	﹤0.01%	2507
2022 Q2	$696K	Buy	38,300 +13,200	+53%	+$274K	﹤0.01%	3455
2022 Q1	$633K	Buy	+25,100	New	+$642K	﹤0.01%	2920
2021 Q4	–	Sell	-10,100	Closed	-$326K	–	5562
2021 Q3	$326K	Buy	+10,100	New	+$335K	﹤0.01%	3596
2019 Q1	–	Sell	-1,600	Closed	-$47K	–	4368
2018 Q4	$47K	Sell	1,600 -3,200	-67%	-$115K	﹤0.01%	3653
2018 Q3	$221K	Buy	+4,800	New	+$213K	﹤0.01%	3161

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PEAK6 Investments's MYGN Position: Q2 2023 in Review

PEAK6 Investments sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 9,900 shares — an estimated $230K sold.

PEAK6 Investments first reported a position in MYGN in Q3 2018 and held it in 4 quarters. The position peaked at $466K in Q4 2018. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

PEAK6 Investments reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
PEAK6 Investments sold 9,900 Myriad Genetics shares in Q2 2023, an estimated $230K.
PEAK6 Investments first reported a position in Myriad Genetics in Q3 2018 and held it in 4 quarters.
PEAK6 Investments's Myriad Genetics position peaked at $466K in Q4 2018.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on PEAK6 Investments's 13F filing for Q2 2023, filed 11 Aug 2023.